Halozyme Therapeutics Inc (HALO)
Total asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 1,015,320 | 829,253 | 660,116 | 443,310 | 267,594 |
| Total assets | US$ in thousands | 2,063,480 | 1,733,270 | 1,841,510 | 1,104,430 | 579,924 |
| Total asset turnover | 0.49 | 0.48 | 0.36 | 0.40 | 0.46 |
December 31, 2024 calculation
Total asset turnover = Revenue ÷ Total assets
= $1,015,320K ÷ $2,063,480K
= 0.49
Total asset turnover is a crucial financial ratio that measures a company's efficiency in generating sales revenue from its total assets. In the case of Halozyme Therapeutics Inc, the trend in total asset turnover over the past five years can be observed.
- In December 31, 2020, the total asset turnover was 0.46, indicating that for every dollar of total assets, the company generated $0.46 in revenue.
- By December 31, 2021, the total asset turnover decreased to 0.40, suggesting a decline in efficiency in utilizing assets to generate revenue.
- This trend continued in December 31, 2022, with the total asset turnover further dropping to 0.36, signaling a potential inefficiency in asset utilization or a decrease in sales relative to total assets.
- However, there was a positive turn in December 31, 2023, where the total asset turnover improved to 0.48, indicating a better utilization of assets to generate sales revenue.
- In the most recent period ending December 31, 2024, the total asset turnover increased slightly to 0.49, showcasing a continued improvement in efficiency in converting total assets into revenue.
Overall, the fluctuation in total asset turnover for Halozyme Therapeutics Inc over the years indicates varying degrees of effectiveness in utilizing its assets to generate sales revenue. It is essential for the company to focus on optimizing asset management to improve this ratio consistently.
Peer comparison
Dec 31, 2024